Natera, Inc. Insider Stock Sale by Sheena Jonathan

In a recent transaction, Sheena Jonathan, Co-Founder of Natera, Inc. (NASDAQ:NTRA), a leader in personalized genetic testing and diagnostics, sold a significant amount of company stock totaling over $2.8 million on September 18, 2024.

The transactions included the sale of multiple blocks of shares at varying prices, ranging from $127.3779 to $128.0748. The total number of shares sold by Jonathan was conducted through several transactions as part of pre-arranged trading plans, but the exact number has not been disclosed.

These trading plans, known as Rule 10b5-1 plans, were adopted by Jonathan on various dates, including some as early as March 13, 2023. Rule 10b5-1 plans allow company insiders to sell shares at predetermined times to avoid allegations of insider trading.

It is noteworthy that some shares sold were indirectly held by trusts for the benefit of Jonathan’s minor children, indicating she has disclaimed beneficial ownership of these securities.

Although this sale represents a significant divestment, Jonathan’s remaining holdings in Natera, Inc. are still substantial. The exact number of shares retained, directly or indirectly, post-sale is detailed in the SEC filing.

Investors closely monitor insider transactions for insights into a company’s valuation and future prospects. However, these may also reflect standard financial planning and diversification strategies.

Natera, Inc. continues to play a crucial role in the medical laboratories industry, offering innovative genetic testing solutions and is based in Austin, Texas, under Delaware jurisdiction.

Recent Developments at Natera

Natera has garnered attention due to various significant developments, reporting a 12% sequential revenue increase and a 58% year-over-year growth, prompting the company to raise its full-year revenue guidance to approximately $1.5 billion. The gross margin expectation is at 55%, alongside record test volumes and rising average selling prices.

Analysts from Piper Sandler, TD Cowen, and Canaccord Genuity maintain positive ratings on Natera’s shares, particularly due to expected impacts from new Galaxy study results and anticipation of presentations at the European Society for Medical Oncology (ESMO). They emphasize Natera’s market-leading position driven by first-mover advantages with its cancer test, Signatera.

Additionally, Natera’s Renasight test received endorsement from the National Kidney Foundation for chronic kidney disease testing. Despite some setbacks, including a delay in the ALTAIR study and non-renewal of the Foundation Medicine partnership, Natera anticipates steady growth, projecting a 40% revenue increase compared to 2023.

Investor Insights

Following recent insider transactions, investors are closely assessing Natera’s financial health and stock performance. Currently, Natera boasts a market capitalization of $15.75 billion, reflecting significant confidence in its market position and growth potential.

While not profitable over the past twelve months, Natera has shown impressive revenue growth, with a 46.13% increase over the last twelve months as of Q2 2024. The company reported a quarterly revenue growth of 58.13% in Q2 2024, signifying strong business momentum.

Analysts have revised their earnings expectations upwards, indicating potential for continued revenue growth or operational improvements. Natera’s stock achieved a 19.3% total return over the last three months and an impressive 170.21% return over the past year, reflecting robust performance in the stock market.

For deeper analysis, additional insights including liquidity, debt levels, and trading multiples can be found on InvestingPro, with further tips available for informed investment decisions.

This article was generated with AI support and reviewed by an editor. For more information, see our T&C.